Main menu button

Nyheter

Equity Research Biosergen: Candidozyma auris on the rise in Europe
17 sep 2025
Equity Research Biosergen: Candidozyma auris on the rise in Europe
Analysmaterial Biosergen
Research update Biosergen: Ongoing development going according to plan
02 sep 2025
Research update Biosergen: Ongoing development going according to plan
Analysmaterial Biosergen
Equity Research Biosergen: Stable quarter with exciting news around the corner
23 maj 2025
Equity Research Biosergen: Stable quarter with exciting news around the corner
Analysmaterial Biosergen
Research update Biosergen: Continued success in India and cash injection
07 mar 2025
Research update Biosergen: Continued success in India and cash injection
Analysmaterial Biosergen
Carlsquare Equity Research interview with Biosergen
11 feb 2025
Carlsquare Equity Research interview with Biosergen
Analysmaterial Biosergen
Research update Biosergen: Promising interim data as BSG005 saves lives
14 nov 2024
Research update Biosergen: Promising interim data as BSG005 saves lives
Analysmaterial Biosergen
Carlsquare Equity Research interview with Biosergen
23 sep 2024
Carlsquare Equity Research interview with Biosergen
Analysmaterial Biosergen
Research update Biosergen: First patient treated in phase Ib study a success
12 sep 2024
Research update Biosergen: First patient treated in phase Ib study a success
Analysmaterial Biosergen
Research update Biosergen: Taking the next clinical step
05 jul 2024
Research update Biosergen: Taking the next clinical step
Analysmaterial Biosergen
Equity Research Biosergen: Study permission received, BSG005 ready for testing in patients
11 jun 2024
Equity Research Biosergen: Study permission received, BSG005 ready for testing in patients
Analysmaterial Biosergen
Research update Biosergen: Rights issue to fund crucial step for lead project
13 mar 2024
Research update Biosergen: Rights issue to fund crucial step for lead project
Analysmaterial Biosergen
Carlsquare Equity Research intervju med Biosergen (Engelska)
07 mar 2024
Carlsquare Equity Research intervju med Biosergen (Engelska)
Analysmaterial Biosergen
Equity research Biosergen: Rights issue to fund the next clinical step
02 feb 2024
Equity research Biosergen: Rights issue to fund the next clinical step
Analysmaterial Biosergen
Analys Biosergen: Licensiering till Alkem och inskickad CTA
16 jan 2024
Analys Biosergen: Licensiering till Alkem och inskickad CTA
Analysmaterial Biosergen
Biosergen at Carlsquare Nordic life science investor day
08 dec 2023
Biosergen at Carlsquare Nordic life science investor day
Analysmaterial Biosergen
Analys Biosergen, kv2 2023: lägre kostnader med förseningar i pipeline
16 aug 2023
Analys Biosergen, kv2 2023: lägre kostnader med förseningar i pipeline
Analysmaterial Biosergen
Equity research Biosergen: Plans for speedy development of lead candidate
29 mar 2023
Equity research Biosergen: Plans for speedy development of lead candidate
Analysmaterial Biosergen
Initiation of coverage, Biosergen: Make antifungals great again
20 mar 2023
Initiation of coverage, Biosergen: Make antifungals great again
Analysmaterial Biosergen